Emedgene
Emedgene uses AI to automatically interpret genetic tests, so that health organizations can scale personalized care to wider populations.
Emedgene has raised €5.2M across 1 funding round from 1 investor, most recently a Series A round in Jan 2019. Based in Mazor, Israel; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€5.2M
€5,240,175
Funding rounds
1
Investors
1
distinct backers
Active since
2019-01
latest 2019-01
Funding by year
EUR raised per yearEmedgene — funding by year — interactive chart.
Data table
| Emedgene — funding by year | |
|---|---|
| 2018 | €5.2M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series A | €5.2M | Olive Tree Ventures | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Trax€789MIsrael · Software
Global coverage: FundingData